Core Insights - Tempus AI, Inc. and Merck have announced an expanded multi-year collaboration to enhance the discovery and development of precision medicine biomarkers, particularly in oncology [1][2] - The partnership aims to leverage Tempus' de-identified multimodal datasets and advanced AI capabilities to improve patient outcomes and accelerate the development of candidate therapies [2][3] Company Overview - Tempus is a technology company focused on advancing precision medicine through AI applications in healthcare, boasting one of the largest libraries of multimodal data [4] - The company provides AI-enabled solutions to physicians, aiming to personalize patient care and facilitate the discovery and development of optimal therapeutics [4] Collaboration Details - Under the agreement, Merck will utilize Tempus' Lens Platform and Workspaces environment, which is powered by a significant GPU infrastructure, to conduct complex analyses on multimodal datasets [2] - The collaboration is expected to enhance Merck's precision oncology strategy by applying AI/ML capabilities to discover novel biomarkers and inform drug combinations in their early pipeline [3]